Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon in China

This article was originally published in The Tan Sheet

Executive Summary

Company to operate as wholesaler/retailer under a new business licensing agreement between the company and the Chinese government following an April 21 ban on direct selling in the country. Avon will operate as a wholesaler to Chinese retail stores and convert its approximately 75 distribution centers into retail stores to directly serve customers. Avon was the first direct seller in China in 1990 and today boasts 50,000 representatives. Company sales in China in 1997 were $75 mil., or about 1.5% of the company's total. Avon has invested between $70 mil. and $75 mil. in China in the last eight years. Amway also was offered the wholesaler/retailer option, but the company has decided to continue negotiations on its "optimal plan" that would continue to provide income opportunities for the 80,000 Amway reps in China. The company has invested $100 mil. in China in the last five years...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088525

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel